Literature DB >> 21677135

Anti-CD8 antibodies can trigger CD8+ T cell effector function in the absence of TCR engagement and improve peptide-MHCI tetramer staining.

Mathew Clement1, Kristin Ladell, Julia Ekeruche-Makinde, John J Miles, Emily S J Edwards, Garry Dolton, Tamsin Williams, Andrea J A Schauenburg, David K Cole, Sarah N Lauder, Awen M Gallimore, Andrew J Godkin, Scott R Burrows, David A Price, Andrew K Sewell, Linda Wooldridge.   

Abstract

CD8(+) T cells recognize immunogenic peptides presented at the cell surface bound to MHCI molecules. Ag recognition involves the binding of both TCR and CD8 coreceptor to the same peptide-MHCI (pMHCI) ligand. Specificity is determined by the TCR, whereas CD8 mediates effects on Ag sensitivity. Anti-CD8 Abs have been used extensively to examine the role of CD8 in CD8(+) T cell activation. However, as previous studies have yielded conflicting results, it is unclear from the literature whether anti-CD8 Abs per se are capable of inducing effector function. In this article, we report on the ability of seven monoclonal anti-human CD8 Abs to activate six human CD8(+) T cell clones with a total of five different specificities. Six of seven anti-human CD8 Abs tested did not activate CD8(+) T cells. In contrast, one anti-human CD8 Ab, OKT8, induced effector function in all CD8(+) T cells examined. Moreover, OKT8 was found to enhance TCR/pMHCI on-rates and, as a consequence, could be used to improve pMHCI tetramer staining and the visualization of Ag-specific CD8(+) T cells. The anti-mouse CD8 Abs, CT-CD8a and CT-CD8b, also activated CD8(+) T cells despite opposing effects on pMHCI tetramer staining. The observed heterogeneity in the ability of anti-CD8 Abs to trigger T cell effector function provides an explanation for the apparent incongruity observed in previous studies and should be taken into consideration when interpreting results generated with these reagents. Furthermore, the ability of Ab-mediated CD8 engagement to deliver an activation signal underscores the importance of CD8 in CD8(+) T cell signaling.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21677135      PMCID: PMC3145095          DOI: 10.4049/jimmunol.1003941

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  59 in total

1.  Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation.

Authors:  Michael R Betts; Jason M Brenchley; David A Price; Stephen C De Rosa; Daniel C Douek; Mario Roederer; Richard A Koup
Journal:  J Immunol Methods       Date:  2003-10-01       Impact factor: 2.303

Review 2.  The T cell receptor as a multicomponent signalling machine: CD4/CD8 coreceptors and CD45 in T cell activation.

Authors:  C A Janeway
Journal:  Annu Rev Immunol       Date:  1992       Impact factor: 28.527

3.  Evidence for a regulatory role of the T8 (CD8) antigen in antigen-specific and anti-T3-(CD3)-induced lytic activity of allospecific cytotoxic T lymphocyte clones.

Authors:  G A Van Seventer; R A Van Lier; H Spits; P Ivanyi; C J Melief
Journal:  Eur J Immunol       Date:  1986-11       Impact factor: 5.532

4.  Human CD8 co-receptor is strictly involved in MHC-peptide tetramer-TCR binding and T cell activation.

Authors:  Rita Campanelli; Belinda Palermo; Silvia Garbelli; Stefania Mantovani; Patrizia Lucchi; Antje Necker; Erica Lantelme; Claudia Giachino
Journal:  Int Immunol       Date:  2002-01       Impact factor: 4.823

5.  Germ line-governed recognition of a cancer epitope by an immunodominant human T-cell receptor.

Authors:  David K Cole; Fang Yuan; Pierre J Rizkallah; John J Miles; Emma Gostick; David A Price; George F Gao; Bent K Jakobsen; Andrew K Sewell
Journal:  J Biol Chem       Date:  2009-07-15       Impact factor: 5.157

6.  Essential role of CD8 palmitoylation in CD8 coreceptor function.

Authors:  A Arcaro; C Grégoire; N Boucheron; S Stotz; E Palmer; B Malissen; I F Luescher
Journal:  J Immunol       Date:  2000-08-15       Impact factor: 5.422

7.  Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists.

Authors:  Fred Lühder; Yun Huang; Kevin M Dennehy; Christine Guntermann; Ingrid Müller; Erna Winkler; Thomas Kerkau; Shinji Ikemizu; Simon J Davis; Thomas Hanke; Thomas Hünig
Journal:  J Exp Med       Date:  2003-04-21       Impact factor: 14.307

8.  Engagement of CD4 and CD8 expressed on immature thymocytes induces activation of intracellular tyrosine phosphorylation pathways.

Authors:  A Veillette; J C Zúñiga-Pflücker; J B Bolen; A M Kruisbeek
Journal:  J Exp Med       Date:  1989-11-01       Impact factor: 14.307

9.  Positive and negative selection in transgenic mice expressing a T-cell receptor specific for influenza nucleoprotein and endogenous superantigen.

Authors:  C Mamalaki; J Elliott; T Norton; N Yannoutsos; A R Townsend; P Chandler; E Simpson; D Kioussis
Journal:  Dev Immunol       Date:  1993

10.  Activation of rat T lymphocytes by anti-CD2 monoclonal antibodies.

Authors:  S J Clark; D A Law; D J Paterson; M Puklavec; A F Williams
Journal:  J Exp Med       Date:  1988-06-01       Impact factor: 14.307

View more
  18 in total

1.  Testing for HLA/peptide tetramer-binding to the T cell receptor complex on human T lymphocytes.

Authors:  Pauline Weder; Ton N M Schumacher; Hergen Spits; Rosalie M Luiten
Journal:  Results Immunol       Date:  2012-05-10

Review 2.  The molecular determinants of CD8 co-receptor function.

Authors:  David K Cole; Bruno Laugel; Mathew Clement; David A Price; Linda Wooldridge; Andrew K Sewell
Journal:  Immunology       Date:  2012-10       Impact factor: 7.397

3.  Prothymosin Alpha: A Novel Contributor to Estradiol Receptor Alpha-Mediated CD8+ T-Cell Pathogenic Responses and Recognition of Type 1 Collagen in Rheumatic Heart Valve Disease.

Authors:  Livia S A Passos; Prabhash K Jha; Dakota Becker-Greene; Mark C Blaser; Dayanna Romero; Adrien Lupieri; Galina K Sukhova; Peter Libby; Sasha A Singh; Walderez O Dutra; Masanori Aikawa; Robert A Levine; Maria C P Nunes; Elena Aikawa
Journal:  Circulation       Date:  2022-02-14       Impact factor: 29.690

4.  Expression and characterization of soluble epitope-defined major histocompatibility complex (MHC) from stable eukaryotic cell lines.

Authors:  Amanda L Wooster; Trevor S Anderson; Devin B Lowe
Journal:  J Immunol Methods       Date:  2018-10-19       Impact factor: 2.303

Review 5.  More tricks with tetramers: a practical guide to staining T cells with peptide-MHC multimers.

Authors:  Garry Dolton; Katie Tungatt; Angharad Lloyd; Valentina Bianchi; Sarah M Theaker; Andrew Trimby; Christopher J Holland; Marco Donia; Andrew J Godkin; David K Cole; Per Thor Straten; Mark Peakman; Inge Marie Svane; Andrew K Sewell
Journal:  Immunology       Date:  2015-09       Impact factor: 7.215

6.  Comparison of peptide-major histocompatibility complex tetramers and dextramers for the identification of antigen-specific T cells.

Authors:  G Dolton; A Lissina; A Skowera; K Ladell; K Tungatt; E Jones; D Kronenberg-Versteeg; H Akpovwa; J M Pentier; C J Holland; A J Godkin; D K Cole; M A Neller; J J Miles; D A Price; M Peakman; A K Sewell
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

7.  Antibody stabilization of peptide-MHC multimers reveals functional T cells bearing extremely low-affinity TCRs.

Authors:  Katie Tungatt; Valentina Bianchi; Michael D Crowther; Wendy E Powell; Andrea J Schauenburg; Andrew Trimby; Marco Donia; John J Miles; Christopher J Holland; David K Cole; Andrew J Godkin; Mark Peakman; Per Thor Straten; Inge Marie Svane; Andrew K Sewell; Garry Dolton
Journal:  J Immunol       Date:  2014-12-01       Impact factor: 5.422

8.  Targeted suppression of autoreactive CD8+ T-cell activation using blocking anti-CD8 antibodies.

Authors:  Mathew Clement; James A Pearson; Stephanie Gras; Hugo A van den Berg; Anya Lissina; Sian Llewellyn-Lacey; Mark D Willis; Tamsin Dockree; James E McLaren; Julia Ekeruche-Makinde; Emma Gostick; Neil P Robertson; Jamie Rossjohn; Scott R Burrows; David A Price; F Susan Wong; Mark Peakman; Ania Skowera; Linda Wooldridge
Journal:  Sci Rep       Date:  2016-10-17       Impact factor: 4.379

9.  Cell type specific gene delivery by lentiviral vectors: New options in immunotherapy.

Authors:  Qi Zhou; Christian J Buchholz
Journal:  Oncoimmunology       Date:  2013-01-01       Impact factor: 8.110

10.  Identification of human viral protein-derived ligands recognized by individual MHCI-restricted T-cell receptors.

Authors:  Barbara Szomolay; Jie Liu; Paul E Brown; John J Miles; Mathew Clement; Sian Llewellyn-Lacey; Garry Dolton; Julia Ekeruche-Makinde; Anya Lissina; Andrea J Schauenburg; Andrew K Sewell; Scott R Burrows; Mario Roederer; David A Price; Linda Wooldridge; Hugo A van den Berg
Journal:  Immunol Cell Biol       Date:  2016-02-05       Impact factor: 5.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.